Annual FCF
-$36.92 M
+$22.66 M+38.03%
December 31, 2022
Summary
- As of February 10, 2025, NBRV annual free cash flow is -$36.92 million, with the most recent change of +$22.66 million (+38.03%) on December 31, 2022.
- During the last 3 years, NBRV annual FCF has risen by +$35.03 million (+48.69%).
Performance
NBRV Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly FCF
-$5.62 M
-$3.99 M-244.00%
March 31, 2023
Summary
- As of February 10, 2025, NBRV quarterly free cash flow is -$5.62 million, with the most recent change of -$3.99 million (-244.00%) on March 31, 2023.
- Over the past year, NBRV quarterly FCF has increased by +$10.28 million (+64.66%).
Performance
NBRV Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM FCF
-$26.64 M
+$10.28 M+27.85%
March 31, 2023
Summary
- As of February 10, 2025, NBRV TTM free cash flow is -$26.64 million, with the most recent change of +$10.28 million (+27.85%) on March 31, 2023.
- Over the past year, NBRV TTM FCF has increased by +$27.10 million (+50.43%).
Performance
NBRV TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
NBRV Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +38.0% | +64.7% | +50.4% |
| 3 y3 years | +48.7% | +80.0% | +66.5% |
| 5 y5 years | +47.6% | +65.9% | +63.0% |
NBRV Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +61.4% | +244.0% | +183.0% | at high | +123.7% |
| 5 y | 5-year | at high | +94.9% | +244.0% | +401.3% | at high | +198.3% |
| alltime | all time | +608.7% | +97.6% | +244.0% | +401.3% | +939.1% | +204.6% |
Nabriva Therapeutics Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$5.62 M(+244.0%) | -$26.64 M(-27.9%) |
| Dec 2022 | -$36.92 M(-38.0%) | -$1.63 M(-74.0%) | -$36.92 M(-10.8%) |
| Sep 2022 | - | -$6.28 M(-52.1%) | -$41.41 M(-14.4%) |
| Jun 2022 | - | -$13.10 M(-17.6%) | -$48.37 M(-10.0%) |
| Mar 2022 | - | -$15.90 M(+159.6%) | -$53.74 M(-9.8%) |
| Dec 2021 | -$59.58 M(-16.6%) | -$6.13 M(-53.7%) | -$59.58 M(-10.9%) |
| Sep 2021 | - | -$13.24 M(-28.3%) | -$66.84 M(+1.0%) |
| Jun 2021 | - | -$18.47 M(-15.0%) | -$66.20 M(+1.8%) |
| Mar 2021 | - | -$21.75 M(+62.5%) | -$65.01 M(-9.0%) |
| Dec 2020 | -$71.44 M(-0.7%) | -$13.38 M(+6.2%) | -$71.44 M(-2.8%) |
| Sep 2020 | - | -$12.61 M(-27.0%) | -$73.51 M(-2.9%) |
| Jun 2020 | - | -$17.28 M(-38.7%) | -$75.68 M(-4.8%) |
| Mar 2020 | - | -$28.18 M(+82.4%) | -$79.47 M(+10.4%) |
| Dec 2019 | -$71.95 M(-1.4%) | -$15.45 M(+4.6%) | -$71.95 M(-8.6%) |
| Sep 2019 | - | -$14.78 M(-29.8%) | -$78.75 M(-3.0%) |
| Jun 2019 | - | -$21.06 M(+1.9%) | -$81.15 M(+5.2%) |
| Mar 2019 | - | -$20.67 M(-7.1%) | -$77.12 M(+5.7%) |
| Dec 2018 | -$72.95 M | -$22.25 M(+29.6%) | -$72.95 M(-2.5%) |
| Sep 2018 | - | -$17.17 M(+0.8%) | -$74.81 M(+1.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | - | -$17.03 M(+3.2%) | -$73.59 M(+1.8%) |
| Mar 2018 | - | -$16.50 M(-31.6%) | -$72.31 M(+2.5%) |
| Dec 2017 | -$70.52 M(+44.1%) | -$24.11 M(+51.2%) | -$70.52 M(+23.4%) |
| Sep 2017 | - | -$15.95 M(+1.3%) | -$57.16 M(+6.0%) |
| Jun 2017 | - | -$15.75 M(+7.1%) | -$53.95 M(+2.4%) |
| Mar 2017 | - | -$14.71 M(+36.8%) | -$52.69 M(+7.7%) |
| Dec 2016 | -$48.93 M(+121.7%) | -$10.75 M(-15.6%) | -$48.93 M(+16.8%) |
| Sep 2016 | - | -$12.74 M(-12.1%) | -$41.90 M(+16.6%) |
| Jun 2016 | - | -$14.49 M(+32.4%) | -$35.92 M(+17.6%) |
| Mar 2016 | - | -$10.95 M(+193.8%) | -$30.54 M(+38.3%) |
| Dec 2015 | -$22.07 M(+92.0%) | -$3.73 M(-44.9%) | -$22.07 M(+2.5%) |
| Sep 2015 | - | -$6.76 M(-25.7%) | -$21.53 M(+24.8%) |
| Jun 2015 | - | -$9.11 M(+266.8%) | -$17.25 M(+51.1%) |
| Mar 2015 | - | -$2.48 M(-22.1%) | -$11.42 M(-0.7%) |
| Dec 2014 | -$11.50 M(+120.7%) | -$3.19 M(+28.5%) | -$11.50 M(+38.3%) |
| Sep 2014 | - | -$2.48 M(-24.2%) | -$8.31 M(+42.5%) |
| Jun 2014 | - | -$3.27 M(+27.5%) | -$5.83 M(+127.5%) |
| Mar 2014 | - | -$2.56 M | -$2.56 M |
| Dec 2013 | -$5.21 M | - | - |
FAQ
- What is Nabriva Therapeutics annual free cash flow?
- What is the all time high annual FCF for Nabriva Therapeutics?
- What is Nabriva Therapeutics annual FCF year-on-year change?
- What is Nabriva Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for Nabriva Therapeutics?
- What is Nabriva Therapeutics quarterly FCF year-on-year change?
- What is Nabriva Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for Nabriva Therapeutics?
- What is Nabriva Therapeutics TTM FCF year-on-year change?
What is Nabriva Therapeutics annual free cash flow?
The current annual FCF of NBRV is -$36.92 M
What is the all time high annual FCF for Nabriva Therapeutics?
Nabriva Therapeutics all-time high annual free cash flow is -$5.21 M
What is Nabriva Therapeutics annual FCF year-on-year change?
Over the past year, NBRV annual free cash flow has changed by +$22.66 M (+38.03%)
What is Nabriva Therapeutics quarterly free cash flow?
The current quarterly FCF of NBRV is -$5.62 M
What is the all time high quarterly FCF for Nabriva Therapeutics?
Nabriva Therapeutics all-time high quarterly free cash flow is -$1.63 M
What is Nabriva Therapeutics quarterly FCF year-on-year change?
Over the past year, NBRV quarterly free cash flow has changed by +$10.28 M (+64.66%)
What is Nabriva Therapeutics TTM free cash flow?
The current TTM FCF of NBRV is -$26.64 M
What is the all time high TTM FCF for Nabriva Therapeutics?
Nabriva Therapeutics all-time high TTM free cash flow is -$2.56 M
What is Nabriva Therapeutics TTM FCF year-on-year change?
Over the past year, NBRV TTM free cash flow has changed by +$27.10 M (+50.43%)